Info
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.
8 anni fa
#acquired, #cancer, #cancergrace, #dana, #egfr, #farber, #geoffrey, #grace, #gracecast, #inhibitor, #institute, #metastasis, #mutation, #oxnard, #progression, #resistance, #significant, #solitary, #t790m, #tki
Scopri di più
Cerca
